GlobeNewsWire
10 Nov 2026, 23:48 UTC · 17h ago
Impact · against what's priced in
The grant of US patent 12,788,796 provides Immutep with a stronger intellectual property moat for Efti-based combination therapies. This expands the potential exclusivity runway and increases the company's attractiveness to potential strategic partners.
No priced-in read yet
What the story claims
1 claim · scored −1 bearish … +1 bullish · 1 new · 0 priced in
Immutep was granted US patent 12,788,796 for combined preparations to treat cancer or infection using Efti-based therapies.
Newannounced today Nov 11, 2026
So whatSecuring US IP extends the exclusivity runway for potential combination partners beyond the base Efti patents.
More positive than 76% of claims this week
Which stocks this story touches
Continue reading
5 related stories
The USPTO grant of patent 12,788,796 for combined preparations to treat cancer or infection secures additional IP protection in the US, extending the exclusivity runway for combination therapies.
Read from the article alone
Scored by the NIS engine · methodology.
More positive than 89% of ticker scores this week
The company was granted a new USPTO patent for cancer and infection treatments, strengthening its intellectual property portfolio.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Finbold
1h ago
—
No price for IMM right now — the quote feed didn't answer.
IMM chart →
